anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The current treatment options for metastatic colon cancer are in need of further improvement. The three-drug combination of oxaliplatin with 5-FU/LV (fluorouracil/leucovorin) in the second-line treatment of metastatic colorectal cancer have shown a significant increase in response rate compared to 5-FU/LV alone. Oxaliplatin has recently been FDA-approved for this indication and is now a standard first-line agent in combination with a fluoropyrimidine. Cetuximab, a chimeric monoclonal antibody against the growth factor receptor, has shown activity with and without irinotecan in subjects with colorectal cancer refractory to irinotecan alone. Cetuximab has also been shown to be safe and effective when administered with infusional 5-FU/folinic acid plus irinotecan. These results suggest that the addition of cetuximab to fluoropyrimidine/oxaliplatin-based regimen in the 1st line setting should be explored. The use of the oral fluoropyrimidine, capecitabine, to replace infusional 5FU has been widely used for improved convenience and possible safety. We have chosen a modified biweekly CapeOx (capecitabine plus oxaliplatin) regimen due to its improved tolerance and response rate with a fixed dose of capecitabine given its widespread practice and ease of use.
Cognitive-behavioural therapy for eating disorders (CBT-ED) is currently one of the NICE (2017) recommended treatments for anorexia nervosa and the only treatment recommended for bulimia nervosa, binge-eating disorder and other specified feeing and eating disorders. When clinicians adhere to evidence-based CBT-ED treatment manuals, CBT-ED has shown demonstrable levels of effectiveness in a range of eating disorders, comparable to outcomes in controlled research settings. A key component of CBT-ED found so effective in the treatment of eating disorders is a stronger focus on behavioural change tasks which is key for changing biased thinking. However, clinicians often drift from using behavioural change components and instead focus more on the cognitive aspects of therapy, or indeed drift away from treatment manuals substantially. Therefore, a suitable measure that can accurately assess how well a clinician is delivering the therapeutic competences that ensures patients are receiving evidence-based CBT-ED thus providing them with the best chance of reaching maximum recovery is important. Whilst numerous scales have been developed, none have yet been found suitable for eating disorders, as they do not have a strong focus on the key behavioural aspects of CBT-ED. Therefore, a team of clinical researchers developed the Cognitive Behaviour Therapy Scale for Eating Disorders (CBTS-ED). This pilot study will use CBT-ED therapy session audio-recordings, and different expert and non-expert raters to a) assess the inter-rater reliability of the CBTS-ED and b) assess whether the CBTS-ED can accurately detect improvement in competence among clinicians currently undergoing post-graduate diploma training in CBT-ED. The findings from this study will provide information about the reliability of the CBTS-ED scale and its possible future uses in predicting patient outcomes.

National Institute for Health and Care Excellence (2017). Eating disorders: recognition and treatment (NICE guideline NG69). Available at: https://www.nice.org.uk/guidance/ng69
Subjects participate in two study periods: During the first period, they receive a single oral dose of midazolam on Day 1. During the second period, they receive oral selexipag alone from Day 1 to Day 11 and selexipag + midazolam on Day 12. There is a washout period of 14 to 21 days between the two periods.
An example method for selective content provision for members of a health management system involves receiving demographic information related to a member. The method also involves receiving health information related to the member. The health information includes a medical condition code, a health risk assessment, health insurance plan information, and health insurance claim data. The method also involves determining a member profile using the demographic information and the health information. The method also involves selecting content for the member based on the member profile. The method also involves providing the selected content to a computing device associated with the member.
This study was to develop and evaluate the self-efficacy and resilience of the Breast Cancer Self-Care App in newly diagnosed breast cancer patients undergoing chemotherapy. In the first phase of this study, develop a prototype the Breast Cancer Self-Care App by conducting patients interviews. In the second phase, an experimental two-group pretest-posttest quantitative study design to evaluate the self-efficacy and resilience of the Breast Cancer Self-Care App in newly diagnosed breast cancer patients undergoing chemotherapy. The patients were randomized to the experimental and control groups. Patients in the control group received general routine care and patients in the experimental group received general routine care plus the Breast Cancer Self-Care App intervention. Both groups completed a basic demographics, self-efficacy and resilience questionnaires at the pre-test and after four weeks.
Multiple bacterial genera take advantage of the multifunctional autoprocessing repeats-in-toxin (MARTX) toxin to invade host cells. Secretion of the MARTX toxin by Vibrio vulnificus, a deadly opportunistic pathogen that causes primary septicemia, the precursor of sepsis, is a major driver of infection; however, the molecular mechanism via which the toxin contributes to septicemia remains unclear. Here, we report the crystal and cryo-electron microscopy (EM) structures of a toxin effector duet comprising the domain of unknown function in the first position (DUF1)/Rho inactivation domain (RID) complexed with human targets. These structures reveal how the duet is used by bacteria as a potent weapon. The data show that DUF1 acts as a RID-dependent transforming NADase domain (RDTND) that disrupts NAD+ homeostasis by hijacking calmodulin. The cryo-EM structure of the RDTND-RID duet complexed with calmodulin and Rac1, together with immunological analyses in vitro and in mice, provide mechanistic insight into how V. vulnificus uses the duet to suppress ROS generation by depleting NAD(P)+ and modifying Rac1 in a mutually-reinforcing manner that ultimately paralyzes first line immune responses, promotes dissemination of invaders, and induces sepsis. These data may allow development of tools or strategies to combat MARTX toxin-related human diseases.
<P>PROBLEM TO BE SOLVED: To provide a medicine for improving or preventing (A) diarrhea and/or (B) digestive symptoms due to intestinal abnormal fermentation, characteristic to sugar alcohols taken as medicines or foods.  <P>SOLUTION: One or more polysaccharides are compounded as an active ingredient in a constant ratio to sugar alcohols or separately taken to reduce or eliminate side effects consisting of (A) diarrhea and/or (B) digestive symptoms, such as gastrointestinal symptoms, due to intestinal abnormal fermentation, characteristic to the sugar alcohols, as main complaints. The characteristics of the polysaccharides are utilized, and the two or more polysaccharides are combined. Both an antidiarrheic action and an intestinal function-controlling action can simultaneously be realized in a smaller amount than that in a case using a polysaccharide singly. The medicine can be changed into a form capable of being easily taken.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Similar to diabetes and unlike many pathogen-induced diseases, endometriosis is likely a result of maladaptation to the evolutionary heritage of humans. The objective of this article is to review the literature and improve understanding of the evolutionary factors behind endometriosis, leading to more effective prevention and treatment approaches. In primates, spontaneous decidualization of the endometrium evolved to ensure optimal implantation of a limited number of early embryos, unlike many non-primates which depend on early embryos to induce decidualization and subsequent pregnancy. Spontaneous decidualization results in menstrual bleeding when embryo implantation does not occur, and endometriosis is commonly believed to be caused by retrograde menstruation. Although direct evidence is lacking, it is likely that hunter-gatherer women experienced fewer menstrual periods due to pregnancy shortly after menarche, followed by repeated pregnancies and lactation. However, the mismatch between the evolved uterine physiology and rapid societal changes has led to modern women delaying pregnancy and experiencing numerous menstrual periods, potentially increasing the incidence of endometriosis. The symptoms of endometriosis are often managed by suppressing menstruation through systemic hormonal treatments, but these may have side effects. For patients with a family history of endometriosis or in the early stages of the disease, intrauterine devices releasing progesterone locally could prevent uterine bleeding and the development of endometriosis while preserving fertility and minimizing side effects.
Diabetic foot occurs in 15% of diabetic population (3) and 15% of the diabetic foot patients end up with lower limb amputation. Peripheral neuropathy (sensory, motor and autonomic), peripheral vascular disease, trauma, infection and poor wound healing all contribute to diabetic foot problem.

Peripheral neuropathy could be evaluated in a variety of ways, including vibratory thresholds, thermal thresholds, pressure perception thresholds, muscle strength. All these predict foot ulceration to some degree(1). Motor nerve conduction velocity is an independent predictor for the development of new foot ulcer in diabetic population.

For more detailed structural study of neuropathy in diabetic patient, we could use skin biopsy method. Skin biopsy with PGP9.5 immunohistochemistry has been demonstrated by ultrastructural studies to label the terminal portions of both small myelinated and unmyelinated nerve in the epidermis . Intra-epidermal nerve fiber (IENF) density is reduced in patient with impaired glucose tolerance and clinically overt diabetes . Previous IENF density study was performed in diabetic patients with sensory symptom but no foot ulcer. Now we tried to evaluate IENF density in severe diabetic foot patient who received below knee amputation. Skin biopsy willl be performed at amputated leg. The skin biopsy area will be located at lateral side of distal leg, 10 cm above the lateral malleolus as previous protocol of our group . Underlying sural nerve and posterior tibial nerve will be also harvested for further ultra-structural study. The result will be compared to the control group which were recruited from a previously described cohort matched by gender and age.
Patients receive bevacizumab IV over 30-90 minutes on weeks 1 and 3 and docetaxel IV over 60 minutes on weeks 1, 2, and 3. Treatment repeats every 4 weeks for up to 12 courses in the absence of unacceptable toxicity or disease progression.
BACKGROUND: Tumor necrosis factor-alpha (TNF-α) is a critical pro-inflammatory cytokine, and its abnormal production is associated with several immune mediated inflammatory diseases (IMID). Biological anti-TNF-α therapy includes treatment with monoclonal antibodies such as infliximab which have proven successful and are well-tolerated in most patients. Unfortunately, some patients may not respond to therapy (primary non-responders) or may lose sensitivity to the biological agent over time (early and late secondary non-responders). Natural products can reduce inflammation and act synergistically with small molecules or biologics, although evidence remains limited. This study aimed to investigate whether complementary and alternative medicine (CAM) could play a role in infliximab non-responders. Reportedly, cinnamon can help manage chronic inflammatory conditions owing to its anti-inflammatory properties.
METHODS: We studied the synergistic effects of cinnamon and infliximab in vitro using a two-step approach. First, we investigated whether cinnamon and infliximab act synergistically. Second, we selected conditions that supported statistically significant synergy with infliximab and studied the mRNA expression of several genes involved in non-response to infliximab. We used aqueous cinnamon extract (aCE) from Cinnamomum cassia, Cinnamomum zeylanicum, and Cinnamomum loureiroi and bioactive trans-cinnamaldehyde (TCA), cinnamic acid (CA), and eugenol to study the synergy between infliximab and aCE/bioactive compounds using bioassays in fibroblast (L929) and monocytic (U937) cell lines, followed by qPCR for molecular-level insights. TCA, C. cassia aCE, and C. zeylanicum aCE demonstrated a dose-dependent synergistic effect with infliximab. Moreover, we saw differential gene expression for adhesion molecules, apoptotic factors, signaling molecules, and matrix remodelers in presence and absence of aCE/bioactives.
RESULTS: CAM supplementation was most effective with C. cassia aCE, where a synergistic effect was observed for all the tested genes specifically for MMP-1, BcL-xL, Bax and JAK2, followed by TCA, which affected most of the tested genes except TLR-2, MMP1, MMP3, TIMP-1, and BAX, and C. zeylanicum aCE, which did not affect ICAM-1, VCAM-1, TLR-2, TLR-4, MMP1, MMP3, TIMP-1, and STAT3.
CONCLUSION: In conclusion, cinnamon acted synergistically with infliximab to mitigate inflammation when used as an extract. Purified bioactive TCA also showed synergistic activity. Thus, aCE, or cinnamon bioactive may be used as a CAM to improve patients' quality of life.
Provided are a platinum (II) compound having a targeting effect and a derivative thereof, a preparation method, a pharmaceutical composition, and the use. The platinum (II) compound has the following structure. The derivative of the platinum (II) compound relates to isomers of the platinum (II) compound or a mixture thereof. The platinum (II) compound has an active targeting effect, and is capable of inhibiting related protein kinases and cancer cells in a targeted mode. In addition, the chemical structure contains a C=N double bond. A tumor acidic microenvironment can be used to passively target tumors, and tissue toxicity is reduced. The present invention exhibits high-efficiency and low-toxicity anti-tumor characteristics, and can overcome the existing issue of drug resistance of platinum and targeted drugs. In addition, a synthesis method for the platinum (II) compound is simple and easy.
The invention discloses a method for preparing biodegradable ocean antifouling polyurethane hybrid materials and a product thereof. The method for preparing the biodegradable ocean antifouling polyurethane hybrid materials and the product thereof adopt stannous octoate as a catalyst, adopts double hydroxyl functional grapheme which is prepared by adopting reduction grapheme to react with 2, 2-hydroxy benzaldehyde and N-glycine as an initiator, and the initiator triggers L-lactide monomers to prepare graphene grafted poly lactic acids through ring opening polymerization. 1, 4-butanediol and 4, 4-diphenyl methane diisocyanate prepare polyurethane prepolymers containing Isocyanate functional groups on the tail ends through condensation polymerization. The biodegradable ocean antifouling polyurethane hybrid materials are prepared by utilizing a chemical reaction between graphene grafted hydroxyl-terminated poly lactic acids and polyurethane prepolymers. The method for preparing biodegradable ocean antifouling polyurethane hybrid materials and the product thereof improve strength of target materials by leading into grapheme, and the grapheme plays the role of antibacterial function during the degradation process, and control crystallinity and hydrophobic property of grafted poly lactide by adjusting the contents of the grapheme and the L-lactide monomers, thereby effectively adjusting and controlling degradation of polyurethane. hybrid materials which are prepared through the method for preparing biodegradable ocean antifouling polyurethane hybrid materials has excellent mechanical properties and can adjust degradation rate, degradation products are non-toxic and do not pollute the environment, and can be applied in antifouling marine coatings and drug controlled release carriers in a biomedical medical engineering.
Patients receive access to a study-specific control website that has annotated links to existing resources for AYA survivors. After 12 months, patients receive a personalized SCP and have access to the digital INSPIRE intervention program without telehealth calls.
Orthostatic intolerance (OI) is a common problem. Reliable markers of OI are missing, as orthostatic blood pressure and heart rate poorly correlate with orthostatic symptoms. The objective of this study was to assess the relationship between orthostatic lightheadedness and cerebral blood flow. In this retrospective study patients with OI were evaluated at the Autonomic Laboratory of the Department of Neurology, Brigham and Women's Faulkner Hospital, Boston. The 10-minute head-up tilt test was performed as a part of autonomic testing. Orthostatic lightheadedness was evaluated at every minute of the head-up tilt. Heart rate, blood pressure, capnography, and cerebral blood flow velocity (CBFv) in the middle cerebral artery using transcranial Doppler were measured. Repeated-measures design with a linear mixed-effects model was used to evaluate the relationship between orthostatic lightheadedness and hemodynamic variables. Correlation analyses were done by calculating Pearson's coefficient. Twenty-two patients with OI were compared to nineteen controls. Orthostatic CBFv and end-tidal CO2 decreased in OI patients compared to controls (p < 0.001) and predicted orthostatic lightheadedness. Orthostatic heart rate and blood pressure failed to predict orthostatic lightheadedness. The lightheadedness threshold, which marked the onset of lightheadedness, was equal to an average systolic CBFv decrease of 18.92% and end-tidal CO2 of 12.82%. The intensity of lightheadedness was proportional to the CBFv and end-tidal CO2 decline. Orthostatic lightheadedness correlated with systolic CBFv (r=-0.6, p < 0.001) and end-tidal CO2 (r=-0.33, p < 0.001) decline. In conclusion, orthostatic CBFv and end-tidal CO2 changes predict orthostatic lightheadedness and can be used as objective markers of OI.
OBJECTIVES: I. Determine the safety and toxicity of preoperative trastuzumab (Herceptin) and paclitaxel followed by postoperative doxorubicin and cyclophosphamide in women with locally advanced breast cancer with HER2 overexpression. II. Determine tumor response in these patients treated with this regimen. III. Assess the effect of this regimen on tumor histology and the potential molecular determinants of response in these patients.

OUTLINE: Patients receive trastuzumab (Herceptin) IV over 30-90 minutes followed by paclitaxel IV over 60 minutes on day 1. Treatment continues every 7 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity. Patients undergo a modified radical mastectomy or a lumpectomy with axillary node dissection. Beginning 14 days after surgery, patients receive doxorubicin IV and cyclophosphamide IV over 15-30 minutes on day 1. Treatment repeats every 21 days for a total of 4 courses. After completion of chemotherapy, patients with hormone receptor-positive disease receive oral tamoxifen daily for 5 years. Patients are followed at 6 months.

PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study.
Breast carcinoma is the leading factor in women's cancer-related fatalities. Due to its numerous inherent molecular subtypes, breast cancer is an extremely diverse illness. The human epidermal growth factor receptor 2 (HER2) positive subtypes stands out among these subtypes as being especially prone to cancer development and illness recurrence. The regulation of embryonic stem cells' pluripotency and self-renewal is carried out by the SALL4 (Spalt-like transcription factor 4) family member. Numerous molecular pathways operating at the transcriptional, post-transcriptional, and epigenomic levels regulate the expression of SALL4. Many transcription factors control the expression of SALL4, with STAT3 being the primary regulator in hepatocellular carcinoma (HCC) and breast carcinoma. Moreover, this oncogene has been connected to a number of cellular functions, including invasion, apoptosis, proliferation, and resistance to therapy. Reduced patient survival rates and a worse prognosis have been linked to higher levels of SALL4. In order to target the undruggable SALL4 that is overexpressed in breast carcinoma, we investigated the prognostic levels of SALL4 in breast carcinoma and its interaction with various related proteins. Using TIMER 2.0 analysis, the expression pattern of SALL4 was investigated across all TCGA datasets. The research revealed that SALL4 expression was elevated in various cancers. The UALCAN findings demonstrated that SALL4 was overexpressed in all tumor samples including breast cancer especially TNBC (Triple negative breast cancer). The web-based ENRICHR program was used for gene ontology analysis that revealed SALL4 was actively involved in the development of the nervous system, positive regulation of stem cell proliferation, regulation of stem cell proliferation, regulation of the activin receptor signaling pathway, regulation of transcription using DNA templates, miRNA metabolic processes, and regulation of transcription by RNA Polymerase I. Using the STRING database, we analyzed the interaction and involvement of SALL4 with other abruptly activated proteins and used Cytoscape 3.8.0 for visualization. Additionally, using bc-GenExMiner, we studied the impact of SALL4 on pathways abruptly activated in different breast cancer subtypes that revealed SALL4 was highly correlated with WNT2B, NOTCH4, AKT3, and PIK3CA. Furthermore, to target SALL4, we evaluated and analyzed the impact of CLP and its analogues, revealing promising outcomes.
OBJECTIVE: To investigate the reliability of parental recall of birth weight, birth length and gestational age several years after birth.
METHODS: Parentally recalled birth parameters were obtained from the European multicentric cohort study IDEFICS (Identification and prevention of dietary- and lifestyle-induced health effects in children and infants) and compared to the corresponding data externally recorded in the child's medical check-up booklet. The agreement between the two sources was examined using Bland-Altman plots, intraclass correlation coefficients and Cohen's kappa for clinically relevant categories. Additionally, logistic regression models were used to identify factors related to parental recall accuracy.
RESULTS: A total of 4930 children aged 2 to 11 years were included. Accuracy of birth weight within 100 g was 88%, 94% of the recalled birth length was within 2 cm, and 99% of the parents could recall with 2 weeks accuracy how many weeks their child was delivered preterm. Discrepancies of more than two weeks or more than 100 g were more likely in parents of low or medium socioeconomic status. Non-biological parents were 3.4 times more likely to have a discrepancy of more than 100 g compared to biological mothers (95% CI 1.7-6.7). Moreover, parents were less likely to accurately recall their child's birth parameters with increasing number of children within a family.
CONCLUSIONS FOR PRACTICE: In general, parents' information matched well with the medical check-up booklet. However, accuracy varied among different groups which should be taken into consideration when using birth data recalled by parents in studies of child health.